Gilead Reports Positive Phase III HIV Treatment Data, Ends Lung Cancer Study

What happened

Gilead and Merck announced positive Phase III results for a once-weekly oral HIV treatment combining islatravir and lenacapavir, while Gilead terminated a non-small cell lung cancer (NSCLC) study. The once-weekly regimen, if approved, would expand Gilead's HIV treatment portfolio beyond its current oral standard Biktarvy and complement the twice-yearly injectable PrEP lenacapavir (Yeztugo). However, the lung cancer discontinuation highlights persistent oncology pipeline struggles, reinforcing the report's view that diversification remains a long-term challenge. The news does not alter the near-term thesis, which hinges on Yeztugo's adoption curve and payer access, as the once-weekly combo is still early-stage and faces its own regulatory and commercialization hurdles. Overall, Gilead's HIV franchise appears more durable, but the stock's next move depends on Yeztugo's 2026 revenue ramp, not early-stage pipeline data.

Implication

The positive Phase III data for islatravir/lenacapavir supports Gilead's long-term HIV competitiveness, but the near-term investment case centers on Yeztugo's ability to reach the $800 million 2026 target. The NSCLC termination confirms oncology is a persistent drag, reinforcing the need for Yeztugo to succeed to offset cell therapy declines. Until measurable payer access and re-dosing persistence metrics emerge, the risk/reward is balanced, and maintaining a Wait rating is prudent. The new combo does not meaningfully de-risk the stock or change the base-case valuation.

Thesis delta

The positive HIV treatment data modestly increases confidence in Gilead's pipeline depth and extends the HIV franchise's longevity, but it does not alter the core thesis that near-term value creation depends on Yeztugo's commercial ramp. The NSCLC termination reaffirms oncology headwinds, making Yeztugo's success even more critical for a re-rating.